Trials / Unknown
UnknownNCT03602131
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | 30 mg oral twice weekly for 2 weeks |
| DRUG | Cladribine | 6 mg/m2 intravenously once daily for 5 days |
| DRUG | gemcitabine | 2500 mg/m2 intravenously twice weekly for 1 week |
| DRUG | Busulfan | 3.2 mg/kg intravenously once daily for 4 days |
| PROCEDURE | Autologous hematopoietic stem cell transplantation | autologous hematopoietic stem cells infusion after ChiCGB chemotherapy |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2020-12-30
- Completion
- 2021-03-30
- First posted
- 2018-07-26
- Last updated
- 2018-07-26
Source: ClinicalTrials.gov record NCT03602131. Inclusion in this directory is not an endorsement.